Gotham Asset Management’s NovoCure NVCR Stock Holding History

Gotham Asset Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-4,569	Closed	-$531K	–	1209
2021 Q3	$531K	Buy	+4,569	New	+$691K	0.02%	648
2021 Q2	–	Sell	-1,662	Closed	-$220K	–	1075
2021 Q1	$220K	Buy	+1,662	New	+$263K	0.01%	927
2020 Q2	–	Sell	-28,727	Closed	-$1.93M	–	1151
2020 Q1	$1.93M	Sell	28,727 -57,545	-67%	-$4.55M	0.05%	413
2019 Q4	$7.27M	Sell	86,272 -4,539	-5%	-$366K	0.13%	215
2019 Q3	$6.79M	Buy	90,811 +34,402	+61%	+$2.75M	0.12%	219
2019 Q2	$3.57M	Buy	56,409 +49,254	+688%	+$2.5M	0.06%	386
2019 Q1	$345K	Buy	+7,155	New	+$344K	0.01%	959
2018 Q2	–	Sell	-30,924	Closed	-$674K	–	990
2018 Q1	$674K	Sell	30,924 -2,521	-8%	-$54.2K	0.01%	675
2017 Q4	$676K	Sell	33,445 -3,357	-9%	-$64.6K	0.01%	660
2017 Q3	$731K	Buy	36,802 +5,924	+19%	+$116K	0.01%	647
2017 Q2	$534K	Buy	+30,878	New	+$399K	0.01%	734

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gotham Asset Management's NVCR Position: Q4 2021 in Review

Gotham Asset Management sold out of NovoCure (NVCR) in Q4 2021, closing a stake of 4,569 shares — an estimated $531K sold.

Gotham Asset Management first reported a position in NVCR in Q2 2017 and held it in 11 quarters. The position peaked at $7.27M in Q4 2019. 311 funds tracked by Wall St. Rank hold NVCR as of Q4 2021.

Gotham Asset Management reported no remaining NovoCure position as of Q4 2021 after selling out during the quarter.
Gotham Asset Management sold 4,569 NovoCure shares in Q4 2021, an estimated $531K.
Gotham Asset Management first reported a position in NovoCure in Q2 2017 and held it in 11 quarters.
Gotham Asset Management's NovoCure position peaked at $7.27M in Q4 2019.
311 funds tracked by Wall St. Rank held NovoCure as of Q4 2021.

Based on Gotham Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.